DaVita (DVA) Stock Analysis & AI Equity Report
DaVita (DVA) overview
DaVita (DVA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 13,643m and operating profit of USD 2,044m; the year-end share price was 113.61 USD and market capitalisation was USD 7,788m. DaVita is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get DaVita's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About DaVita
DaVita provides kidney care services, including dialysis, related laboratory services, integrated kidney care and disease management. Its care spans outpatient centers, patients’ homes, hospitals and skilled nursing facilities, and includes support for slowing kidney disease progression and transplantation. The company operates dialysis services in the United States and internationally and serves people with chronic kidney disease and kidney failure, alongside nephrology and payor partners.
Generate the DaVita report
DaVita is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for DaVita and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on DaVita
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.